Skip to main content
Mirko Fillbrunn

Education

Ph.D., economics, Boston University; Master’s, mathematics and economics, University of Duisburg-Essen

Summary

Dr. Fillbrunn specializes in health economics and outcomes research (HEOR), biostatistics, and epidemiology. His expertise includes strategically developing and guiding the implementation of analytics throughout the entire product life cycle, including analyses of clinical trials and real-world health care data such as insurance claims, electronic health records, medical charts, and surveys. Dr. Fillbrunn’s contributions have informed clinical regulators and health care payers in both the US and global markets. His research has been published in several peer-reviewed journals and presented at clinical and health economic conferences. Prior to joining Analysis Group, Dr. Fillbrunn was a postdoctoral fellow at Harvard Medical School and Massachusetts General Hospital.

Selected Cases & Publications

Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials

Cancers, 2024
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM

Future Oncology, 2024
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials

PLOS One, 2024
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Benefits of Autoantibody Enrichment in Early Rheumatoid arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials

Rheumatology and Therapy, 2023
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial

Open Forum Infectious Diseases, 2023
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study

Patient Preference and Adherence, 2022
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

BMC Cancer, 2022
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

Cancers (Basel), 2022
Read More

Associated People

Mirko Fillbrunn
Mirko Fillbrunn

Related News

  • Consultants Present on Malignancies, Cell Disorders, and More at 66th ASH Annual Meeting and Exposition
    Read More
  • Analysis Group Consultants to Contribute 18 New Outcomes Research Presentations at 65th American Society of Hematology Annual Meeting and Exposition
    Read More
  • AMCP 2023 Conference to Feature New Outcomes Research from Analysis Group
    Read More
/

Related Events

  • Analysis Group to Present New Outcomes Research at 2024 ASCO Annual Meeting
    Read More
/